The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 20, 2002

AVENTIS PHARMA LTD. AND EISAI CO., LTD. ANNOUNCE COPROMOTION AGREEMENT FOR THE OSTEOPOROSIS THERAPEUTIC AGENT, ACTONELR 2.5 mg

Aventis Pharma Ltd.
Eisai Co., Ltd.
AVENTIS PHARMA LTD. AND EISAI CO., LTD. ANNOUNCE COPROMOTION AGREEMENT FOR THE OSTEOPOROSIS THERAPEUTIC AGENT, ACTONELR 2.5 mg

Tokyo (March 20, 2002) - Aventis Pharma Ltd. of Tokyo (Chairman and President: Peter Loescher) and Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced a copromotion agreement in Japan for the osteoporosis therapeutic agent ACTONELR (generic name: risedronate sodium). ACTONELR was appproved for production and marketing in Japan on January 17, 2002.


Under the terms of the agreement, Aventis Pharma Ltd. will record product sales with copromotion by Eisai Co., Ltd. Eisai will receive a copromotion support fee.


ACTONELR is a bisphosphonate agent which can reduce bone loss and was originally synthesized in the U.S. by Norwich Eaton Pharmaceuticals, now part of Procter & Gamble. In Japan, the agent was co-developed by Ajinomoto Co., Inc., Takeda Chemical Industries, Ltd. and Aventis Pharma Ltd. The product first received approval in 1999 in the U.S. and Europe and is currently marketed in 50 countries worldwide.


ACTONELR, which suppresses bone resorption, is a core strategic product of Aventis Pharma. The copromotion agreement between Eisai, which has experience in the osteoporosis therapeutic area, and Aventis for ACTONELR will enable both companies to rapidly concentrate promotion efforts on key market segments and is expected to contribute to improving the quality of life of patients with osteoporosis.


ACTONELR is a registered trademark of Procter & Gamble.



Aventis Pharma Ltd. conducts the Japanese pharmaceutical business of Aventis. Aventis Pharma is dedicated to treating and preventing human disease through the discovery and development of innovative pharmaceutical products. Aventis focuses on prescription drugs for important therapeutic areas such as oncology, cardiology, diabetes and respiratory disorders as well as on human vaccines. In 2001 Aventis generated sales of euro17.7 billion, invested approximately euro3 billion in research and employed approximately 75,000 in its core business. Aventis corporate headquarters are in Strasbourg, France. For further information contact Communications Department, Aventis Pharma Ltd. 81-3-5571-6314.


Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. The Company reported sales of over $2.9 billion in 2000 with approximately 14 percent of sales spent for research and development. For further information contact Public Relations Department, Eisai Co., Ltd. 81-3-3817-5120.